Therapeutic Leaps To Help Families Thrive

Why Higher Medicine?

point image

We are passionate & ready to bring cures to patients in the fields so close to the goal line.

point image

We see a chance for the next biomedical revolution where others may miss.

point image

We serve higher purposes as each one of us define it, from financial prosperity to human flourishing.

Patients

Investing in the future of medical research starting with  Friedreich's Ataxia.

Friedreich’s Ataxia affects multiple tissues in patients, but lacks an effective treatment addressing all symptoms

Friedreich’s ataxia affects multiple tissues in patients, but lacks an effective treatment addressing all symptoms

Cook A, Giunti P. Br Med Bull 2017,  124(1):19-30
1. Iron-Sulfur Cluster Biogenesis 2. Reactive Oxygen Species

p38 inhibitor can break the maladaptive feedback loop that depresses ISCB1, the primary biochemical defect in FA

p38 inhibitor treatment showed promising efficacy in human FA cells and animal model, and may reverse 31P MRS biomarker in patients

p38 inhibitors are well-characterized in other indications and available for in-licensing to leapfrog into a Phase 2 study in FA

Novel Penn ferroptosis inhibitors for the follow-on program are secured

Cotticelli et al., J Pharmacol Exp Ther 369:47–54, 2019; Cotticelli et al., ACS Chem. Neurosci. 2020, 11, 2535−2542

Additionally, investment in the epigenetic platform now can lead to the next biomedical revolution for many cures

Malachowski et al., Cell 2023 186, 5840–5858.e1–e21

Higher Medicine offers the de-risked and synergetic portfolio

FA clinical development & commercial paths were well established, creating clear value inflection & exit opportunities for investors

High step-up potential in a wide range of indications sharing the same mechanisms

Higher Medicine is led by a team of seasoned pharmaceutical executives and advised by Dr. Wilson and his colleagues who helped pioneer the first & only approved FA drug

Agile and capital-efficient support structure is in place

HM is raising $2M and poised for strategic investors looking to achieve rapid value inflection paired with high upside in the long-run

News

Company Announcements
December 15, 2024

Higher Medicine Secures $500,000 Seed Investment from Desire Ventures

Higher Medicine seed investment secured from Desire Ventures

Higher Medicine
Read more